Clarus Wealth Advisors purchased a new position in Allergan plc (NYSE:AGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,392 shares of the company’s stock, valued at approximately $234,000.
Other large investors have also bought and sold shares of the company. Prestige Wealth Management Group LLC purchased a new position in shares of Allergan in the second quarter worth about $25,000. Old North State Trust LLC raised its stake in Allergan by 172.4% during the third quarter. Old North State Trust LLC now owns 158 shares of the company’s stock worth $27,000 after purchasing an additional 100 shares during the period. Motco purchased a new position in Allergan during the second quarter worth about $29,000. HM Payson & Co. purchased a new position in Allergan during the second quarter worth about $29,000. Finally, Evolution Wealth Advisors LLC purchased a new position in Allergan during the second quarter worth about $30,000. 80.47% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have commented on the stock. SunTrust Banks lifted their target price on shares of Allergan to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, July 3rd. TheStreet raised shares of Allergan from a “d+” rating to a “c” rating in a research note on Friday, July 12th. Mizuho downgraded shares of Allergan from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $171.00 to $188.00 in a research note on Wednesday, June 26th. ValuEngine raised shares of Allergan from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $178.00 target price on shares of Allergan in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, sixteen have given a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $179.15.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $4.34 by $0.04. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. The business had revenue of $4.09 billion during the quarter, compared to analysts’ expectations of $3.93 billion. During the same period last year, the business earned $4.42 earnings per share. The business’s revenue for the quarter was down .8% on a year-over-year basis. As a group, sell-side analysts expect that Allergan plc will post 16.68 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Tuesday, August 13th were given a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.75%. The ex-dividend date was Monday, August 12th. Allergan’s dividend payout ratio is presently 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: Lock-Up Period Expiration
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.